IP Library Granted Patent US 8,404,655
Granted Patent B2
US 8,404,655 · App. 12/600,571 · Granted Mar 26, 2013

Inhibition of palmitoyl acyl transferase expression and/or activity for the regulation of antiproliferative factor activity

Inventors: Susan K. Keay (Ellicott City, MD); David Zacharias (Palm Coast, FL); Sonia L. Planey (St. Augustine, FL)
Assignees: University of Florida Research Foundation, Inc.; University of Maryland; The United States of America as represented by the Department of Veterans Affairs
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,404,655
App. No.
12/600,571
Granted
Mar 26, 2013
Kind
B2
Abstract

The invention generally concerns inhibition of a molecule that has a role in post-translational modification of a receptor for antiproliferative factor (APF) of bladder epithelial cells, thereby modulating the APF. In particular, inhibition of DHHC2 activity and/or ZDHHC2 expression results in modulation of APF receptor activity, and in specific aspects such modulation is therapeutic and/or preventative for a bladder condition, such as interstitial cystitis. In addition, inhibition of CKAP4 palmitoylation in certain cases also decreases its activity as a tPA receptor on smooth muscle cells or surfactant A on type II pneumocytes, and/or generally inhibits its function as a cell membrane receptor, cell chaperone molecule, and/or membrane trafficking agent.

Claims (6)

1. A method of modulating activity of antiproliferative factor in an individual, comprising delivering to the individual a therapeutically effective amount of an agent that inhibits palmitoyl acyl transferase, wherein the palmitoyl acyl transferase is DHHC2.

2. The method of claim 1 , wherein the agent is a nucleic acid, protein, small molecule, or a mixture thereof.

3. The method of claim 1 , wherein the nucleic acid comprises siRNA.

4. The method of claim 1 , wherein the delivering step improves at least one symptom of a bladder condition.

5. The method of claim 4 , wherein the bladder condition is interstitial cystitis.

6. The method of claim 4 , wherein the individual is further provided an additional interstitial cystitis therapy.

Assignments (4)
ASSIGNMENT OF JOINT UNDIVIDED RIGHT, TITLE AND INTEREST Recorded May 2, 2012
From: UNIVERSITY OF MARYLAND, BALTIMORE
To: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS
Reel/Frame 028141/0177 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2010
From: KEAY, SUSAN K.
To: UNIVERSITY OF MARYLAND, BALTIMORE
Reel/Frame 025058/0987 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2010
From: ZACHARIAS, DAVID; PLANEY, SONIA L.
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
Reel/Frame 025059/0115 →
CONFIRMATORY LICENSE Recorded Feb 26, 2010
From: UNIVERSITY OF MARYLAND-BALTIMORE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 023994/0922 →
Continuity (3)
Provisional Application 61012676 · Dec 10, 2007
Provisional Application 60938874 · May 18, 2007
Related Publication 20100190684A1 · Jul 29, 2010